BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 11900220)

  • 1. Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis.
    Aligayer H; Boyd DD; Heiss MM; Abdalla EK; Curley SA; Gallick GE
    Cancer; 2002 Jan; 94(2):344-51. PubMed ID: 11900220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential activation of pp60(c-src) and pp62(c-yes) in human colorectal carcinoma liver metastases.
    Han NM; Curley SA; Gallick GE
    Clin Cancer Res; 1996 Aug; 2(8):1397-404. PubMed ID: 9816313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of specific transcriptional regulators as early predictors of independent prognostic relevance in resected colorectal cancer.
    Maurer GD; Leupold JH; Schewe DM; Biller T; Kates RE; Hornung HM; Lau-Werner U; Post S; Allgayer H
    Clin Cancer Res; 2007 Feb; 13(4):1123-32. PubMed ID: 17317820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens.
    Beyer BC; Heiss MM; Simon EH; Gruetzner KU; Babic R; Jauch KW; Schildberg FW; Allgayer H
    Cancer; 2006 Mar; 106(5):1026-35. PubMed ID: 16435385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Site-specific differences in pp60c-src activity in human colorectal metastases.
    Termuhlen PM; Curley SA; Talamonti MS; Saboorian MH; Gallick GE
    J Surg Res; 1993 Apr; 54(4):293-8. PubMed ID: 7687314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome.
    Skelly MM; Troy A; Duffy MJ; Mulcahy HE; Duggan C; Connell TG; O'Donoghue DP; Sheahan K
    Clin Cancer Res; 1997 Oct; 3(10):1837-40. PubMed ID: 9815571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination analysis of activator protein-1 family members, Sp1 and an activator protein-2alpha-related factor binding to different regions of the urokinase receptor gene in resected colorectal cancers.
    Schewe DM; Biller T; Maurer G; Asangani IA; Leupold JH; Lengyel ER; Post S; Allgayer H
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8538-48. PubMed ID: 16361535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
    Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
    Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential role of TGFbeta1, TGFbeta2 and TGFbeta3 protein expression in colorectal carcinomas. Correlation with classic histopathologic factors and patient survival.
    Tsamandas AC; Kardamakis D; Ravazoula P; Zolota V; Salakou S; Tepetes K; Kalogeropoulou C; Tsota I; Kourelis T; Makatsoris T; Karavias D; Scopa CD; Bonikos DS; Kalofonos HP; Petsas T
    Strahlenther Onkol; 2004 Apr; 180(4):201-8. PubMed ID: 15057430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential expression of alpha-methylacyl-coenzyme A racemase in colorectal carcinoma bears clinical and pathologic significance.
    Lin A; Weiser MR; Klimstra DS; Paty PB; Tang LH; Al-Ahmadie H; Hoo Park S; Guillem JG; Temple L; Wong WD; Gerald WL; Shia J
    Hum Pathol; 2007 Jun; 38(6):850-6. PubMed ID: 17442371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated c-Src protein expression is an early event in colonic neoplasia.
    Iravani S; Mao W; Fu L; Karl R; Yeatman T; Jove R; Coppola D
    Lab Invest; 1998 Mar; 78(3):365-71. PubMed ID: 9520949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome.
    Wang KL; Wu TT; Choi IS; Wang H; Resetkova E; Correa AM; Hofstetter WL; Swisher SG; Ajani JA; Rashid A; Albarracin CT
    Cancer; 2007 Feb; 109(4):658-67. PubMed ID: 17211865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
    Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL
    Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer.
    Siegfried JM; Weissfeld LA; Singh-Kaw P; Weyant RJ; Testa JR; Landreneau RJ
    Cancer Res; 1997 Feb; 57(3):433-9. PubMed ID: 9012470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation.
    Piessen G; Messager M; Leteurtre E; Jean-Pierre T; Mariette C
    Ann Surg; 2009 Dec; 250(6):878-87. PubMed ID: 19855261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leptin expression correlates with favorable clinicopathologic phenotype and better prognosis in colorectal adenocarcinoma.
    Paik SS; Jang SM; Jang KS; Lee KH; Choi D; Jang SJ
    Ann Surg Oncol; 2009 Feb; 16(2):297-303. PubMed ID: 19050975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. For patients with Dukes' B (TNM Stage II) colorectal carcinoma, examination of six or fewer lymph nodes is related to poor prognosis.
    Caplin S; Cerottini JP; Bosman FT; Constanda MT; Givel JC
    Cancer; 1998 Aug; 83(4):666-72. PubMed ID: 9708929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma.
    Cho JY; Chung HC; Noh SH; Roh JK; Min JS; Kim BS
    Cancer; 1997 Mar; 79(5):878-83. PubMed ID: 9041148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative serum levels of CEA and CA 19-9 and their prognostic significance in colorectal carcinoma.
    Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Pahl H; Fateh-Moghadam A
    Anticancer Res; 1997; 17(4B):2935-8. PubMed ID: 9329568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
    Grøndahl-Hansen J; Christensen IJ; Briand P; Pappot H; Mouridsen HT; Blichert-Toft M; Danø K; Brünner N
    Clin Cancer Res; 1997 Feb; 3(2):233-9. PubMed ID: 9815678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.